home / stock / govxw / govxw news

GOVXW News and Press, GeoVax Labs Inc. Warrants From 03/07/22

Stock Information
Company Name: GeoVax Labs Inc. Warrants
Stock Symbol: GOVXW
Market: NASDAQ
Website: geovax.com
Menu
GOVXW GOVXW Quote GOVXW Short GOVXW News GOVXW Articles GOVXW Message Board
Get GOVXW Alerts

News, Short Squeeze, Breakout and More Instantly...
GOVXW - GeoVax Announces Key Staff Appointments

Operational Resources Strengthened in Support of Ongoing Phase 2 Clinical Trials for COVID-19 and Advanced Head & Neck Cancer ATLANTA, GA, March 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing ...
GOVXW - GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update

Conference call to be held Wednesday, March 9, at 4:30 p.m. Eastern Time Atlanta, GA, Feb. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer,...

GOVXW - GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100

Atlanta, GA, Feb. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, announced today that its Chairman & CEO, David Dodd, has been selected as ...

GOVXW - GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference

Atlanta, GA, Feb. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that its Chairman and CEO, David Dodd, will present a company overview a...
GOVXW - GeoVax Announces Closing of $10 Million Private Placement

Atlanta, GA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today the closing of its previously announced private placement for the issuan...

GOVXW - GeoVax Announces $10 Million Private Placement

Atlanta, GA, Jan. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a securities purchase agreement with a single i...

GOVXW - GeoVax Retains CATO SMS to Manage Gedeptin® Phase 1/2 Clinical Trial

Activities Underway to Expand and Accelerate Enrollment of Ongoing Study for Head and Neck Cancer ATLANTA, GA, Jan. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and ca...
GOVXW - GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer

Atlanta, GA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H., to serve as the Co...

GOVXW - GeoVax to Participate in Upcoming Life Sciences Investor Conferences

Conference Presentation to Include Updates on Three Ongoing Phase 2 Clinical Trials for COVID-19 and Cancer Atlanta, GA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunoth...

GOVXW - GeoVax Issues Shareholder Update Letter

Letter from CEO Describes Achievements during 2021 and Sets Forth New Goals for 2022 ATLANTA, GA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines a...
Previous 10 Next 10